We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 62

Ambry Genetics countersues Myriad Genetics in genetic patent infringement suit
  • Shook Hardy & Bacon LLP
  • USA
  • August 15 2013

Responding to the patent infringement claims asserted against it by Myriad Genetics, Ambry Genetics Corp. denies that the 15 patents at issue were


Here, there, & everywhere: jurisdiction & venue in patent cases
  • Shook Hardy & Bacon LLP
  • USA
  • April 30 2016

Venue shopping can exert strong influence on patent suit success, causing litigants, courts, and legislatures to wrestle with boundaries. The Federal


Decoding patent-eligibility of diagnostic methods
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2016

Figuring out whether an invention is patent-worthy has become a bit easier, thanks to the Federal Circuit’s clarifications in Genetic Technologies


Nature of nurture? Myriad decoded for non-biochemists
  • Shook Hardy & Bacon LLP
  • USA
  • July 31 2013

Gene patents became unstable with a clearly worded U.S. Supreme Court decision: "We merely hold that genes and the information they encode are not


Genetic technologies settles infringement suit over non-DNA coding technology
  • Shook Hardy & Bacon LLP
  • USA
  • May 2 2013

Genetic Technologies Ltd. (GTG) has reportedly settled a patent infringement lawsuit filed in late 2012 against PreventionGenetics. While the terms


New infringement lawsuit filed to protect BRCA1 and BRCA2 patents
  • Shook Hardy & Bacon LLP
  • USA
  • June 26 2014

Myriad Genetics has brought a new infringement lawsuit against a company offering a next-generation sequencing test that analyzes the BRCA1 and BRCA2


Second Circuit antitrust decision creates uncer tainty for non-practice of patents
  • Shook Hardy & Bacon LLP
  • USA
  • June 11 2015

The U.S. Court of Appeals for the Second Circuit's recent decision in New York v. Actavis PLC appeared on its face to address a narrow issue of


CRS visiting scholar recommends that Congress clarify patentable subject matter doctrine
  • Shook Hardy & Bacon LLP
  • USA
  • November 15 2012

In a Congressional Research Service paper titled “Mayo v. Prometheus: Implications for Patents, Biotechnology, and Personalized Medicine,” visiting scholar John Thomas considers how the U.S. Supreme Court ruling limiting the patentability of diagnostic methods that simply describe natural phenomena and relations may affect innovation and public health


Federal court upholds FTC rules on reporting certain pharma patent transfers
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

Granting the agency's motion for summary judgment, a federal court in the District of Columbia has upheld the U.S. Federal Trade Commission's (FTC's


Court finds no standing for Consumer Watchdog in stem cell patent appeal
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

The Federal Circuit Court of Appeals has rejected not-for-profit Consumer Watchdog's appeal of the U.S. Patent and Trademark Office's (USPTO's